American Academy of Dermatology, March 27 to 31

Follow Drugslib on

By Physician’s Briefing Staff HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

The annual meeting of the American Academy of Dermatology was held from March 27 to 31 in Denver and attracted clinicians, academicians, allied health professionals, and others interested in dermatology. The conference highlighted recent advances in the diagnosis and management of dermatological conditions.

AAD: Subcutaneous Amlitelimab Aids Atopic Dermatitis Outcomes Through Week 24

WEDNESDAY, April 8, 2026 -- Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe atopic dermatitis (AD), according to the results of three phase 3 studies presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Read Full Text

AAD: Ixekizumab + Tirzepatide Boosts Psoriatic Arthritis Outcomes More Than Ixekizumab Monotherapy

MONDAY, April 6, 2026 -- Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Read Full Text

AAD: Upadacitinib Safe, Effective for Nonsegmental Vitiligo

MONDAY, April 6, 2026 -- Treatment with upadacitinib is safe and effective for adults and adolescents with nonsegmental vitiligo, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Read Full Text

AAD: Zasocitinib Safe, Effective for Moderate-to-Severe Plaque Psoriasis in Adults

FRIDAY, April 3, 2026 -- Once-daily oral zasocitinib (TAK-279), an oral tyrosine kinase 2 inhibitor, provides a durable response in adults with moderate-to-severe plaque psoriasis, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Read Full Text

AAD: Significant Benefits Seen for Brepocitinib 30 mg in Dermatomyositis

WEDNESDAY, April 1, 2026 -- For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant benefits at a 30-mg dose compared with placebo, according to a study published online March 28 in the New England Journal of Medicine to coincide with the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Read Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-11 01:45

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords